Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.

[1]  Annette S. Kim,et al.  Minimal residual disease in myeloma: are we there yet? , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  I. Bruns,et al.  The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  M. Terol,et al.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.

[4]  I. Bruns,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[5]  M. Itälä-Remes,et al.  Depth of response assessed by quantitative ASO‐PCR predicts the outcome after stem cell transplantation in multiple myeloma , 2010, European journal of haematology.

[6]  R. Pieters,et al.  Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.

[7]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[8]  R. Fenk,et al.  Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study , 2008, Hematological oncology.

[9]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[10]  R. Braylan,et al.  Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study , 2008, Leukemia & lymphoma.

[11]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[12]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[13]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[14]  D. Dingli,et al.  Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. , 2005, Blood.

[15]  M. Gordon.  Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .

[16]  Robert A Kyle,et al.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. , 2005, Blood.

[17]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[18]  H. Goldschmidt,et al.  Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Marcos González,et al.  Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. , 2005, Haematologica.

[20]  H. Goldschmidt,et al.  Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma , 2004, British journal of haematology.

[21]  R. Fenk,et al.  Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma , 2004, Hematology.

[22]  U. Steidl,et al.  Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. , 2004, Haematologica.

[23]  M. Boccadoro,et al.  Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. , 2003, Blood.

[24]  H. Johnsen,et al.  Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. , 2003, Blood.

[25]  H. Goldschmidt,et al.  Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation , 2001, Bone Marrow Transplantation.

[26]  A. Órfão,et al.  Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.

[27]  H. Goldschmidt,et al.  Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma , 2000, Bone Marrow Transplantation.

[28]  H. Goldschmidt,et al.  Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[29]  K. Thielemans,et al.  USE OF QUANTITATIVE ASO‐PCR TO PREDICT RELAPSE IN MULTIPLE MYELOMA , 1999, British journal of haematology.

[30]  J. Perkins,et al.  High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency , 1997, Bone Marrow Transplantation.

[31]  F. Prósper,et al.  Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement , 1997, Leukemia.

[32]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[33]  E. Montserrat,et al.  Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Rossi,et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.

[35]  S. Salmon,et al.  Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. , 1975, Annual review of medicine.